Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

HHS Secretary Sebelius Picks Georgetown's Mann To Head Center For Medicaid And State Operations
HHS Secretary Kathleen Sebelius on Friday appointed Cindy Mann, director of Georgetown University"s Center for Children and Families, to head the Center for Medicaid and State Operations, a division of the Centers for Medicare and Medicaid Services, BNA reports. Mann is a former director of the Family and Children"s Health Programs at CMSO from 1999 to 2001. Sebelius said Mann has been "instrumental in recent efforts to expand health care coverage in our country." She added that Mann"s "knowledge of health care issues and management experience will be a great asset to CMSO and to the millions of Americans who rely on Medicaid" (BNA, 6/1).
generic viagra online
Seasonal Flu Vaccine Unlikely To Protect Against New H1N1 Says CDC
According to the US Centers for Disease Control and Prevention (CDC), vaccination with seasonal flu vaccines made for the 2005 to 2009
News of the day
Diaper Alarm For Toilet Training Children
A new study appearing in Neurology and Urodynamics evaluates the use of a daytime diaper that uses a musical "wetting alarm" for children in day-care centers. The findings show that wetting alarm diaper training is an effective option for toilet training in a child-friendly way.
Cardiovascular

Foresight Biotherapeutics Announces Initiation Of Viral Conjunctivitis Clinical Trial

Foresight Biotherapeutics announced that the first patient has been dosed in a viral conjunctivitis clinical trial. Foresight"s proprietary lead compound, FST-100, will be tested in a placebo-controlled, masked, and randomized multicenter clinical study throughout the United States. The primary endpoint of the study is the resolution of clinical signs and symptoms of acute conjunctivitis. Secondary endpoints include a reduction in quantitative PCR (qPCR) viral titers, eradication of infectious virus determined by cell culture immunofluorescence assay (CC-IFA), and safety. The company anticipates enrolling up to 100 patients. This controlled clinical trial follows a successful pilot trial in which the safety and efficacy of FST-100 were demonstrated. In addition, the company recently completed and announced a successful preclinical study in a rabbit model of adenoviral conjunctivitis. Viral conjunctivitis or "pink eye" is the most common eye infection in the developed world. The highly contagious infection is a frequent cause of epidemics in the workplace, schools, medical centers and long term care facilities. Treatment is mostly supportive as there is currently no drug approved by the FDA for viral conjunctivitis. FST-100 is a novel formulation of dexamethasone that includes povidone-iodine. This novel formulation may be able to relieve the discomfort and shorten the course of the illness. Foresight Biotherapeutics looks forward to working with the investigators in conducting this clinical trial and advancing the development of the program. Foresight Biotherapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009